1例伊立替康致结肠癌患者急性肝损伤的药学监护

doi:10.19803/j.1672-8629.20240009

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 693-696.
DOI: 10.19803/j.1672-8629.20240009

1例伊立替康致结肠癌患者急性肝损伤的药学监护

林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳^*

上海市浦东新区公利医院临床药学部,上海200135

收稿日期:2024-01-04 出版日期:2024-06-15 发布日期:2024-06-18
通讯作者: ^*李文艳,女,硕士,主任药师,中药新药与临床药学。 E-mail:liwenyan_linda@163.com
作者简介:林彦馨,女,硕士,药师,临床药学。
基金资助:
上海市浦东新区卫生系统领先人才（PWRI2021-11）

Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan

LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan^*

Department of Clinical Pharmacy, Gongli Hospital of Pudong New Area in Shanghai, Shanghai 200135, China

Received:2024-01-04 Online:2024-06-15 Published:2024-06-18

摘要/Abstract

摘要： 目的探讨临床药师在肿瘤患者肝损伤治疗过程中的作用,为临床药师参与临床实践提供参考。方法临床药师参与1例结肠癌患者使用伊立替康致急性肝损伤的治疗过程,对导致患者急性肝损伤原因进行分析,通过RUCAM因果关系评估量表评估药物与肝损伤因果关系,调整保肝药物治疗方案。结果临床药师通过分析患者急性肝损伤与疾病和药物的相关性,及时为临床提供了保肝药物治疗方案的优化建议,对患者用药进行药学监护,经治疗患者肝功能有明显好转。结论临床药师对肿瘤化疗患者进行密切药学监护,有助于降低不良反应,优化药物治疗效果,提升临床合理用药水平。

关键词: 伊立替康, 肝损伤, 结肠癌, 药品不良反应, 药学监护, 临床药师

Abstract: Objective To explore the role of clinical pharmacists in the treatment of liver injury in tumor patients, and to provide reference for the involvement of clinical pharmacists in clinical practice. Methods Clinical pharmacists participated in the treatment of one case of acute liver injury caused by irinotecan in a colon cancer patient, analyzed the causes of acute liver injury, assessed the causal relationship between the drug and liver injury using the Roussel Uclaf Causality Assessment Method (RUCAM), and adjusted the treatment with liver-protecting drugs. Results By analyzing the correlation between acute liver injury and diseases and drugs, clinical pharmacists quickly recommended optimization of the treatment with liver-protecting drugs, and provided pharmaceutical care for the patient. After treatment, the patient’s liver function was significantly improved. Conclusion Prudent pharmacological monitoring of patients under chemotherapy by clinical pharmacists can help to reduce the incidence of adverse reactions, optimize the effect of drug therapy, and improve the level of rational clinical use of drugs.

Key words: irinotecan, liver injury, colon cancer, adverse drug reaction, pharmaceutical care, clinical pharmacist

中图分类号:

R994.11

林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.

LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan. Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240009

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I6/693

参考文献

[1] YU SY, YAO Y.Expert Consensus on Prevention and Treatment of Cancer Drug-Related Liver Injury (肿瘤药物相关性肝损伤防治专家共识)[M]. Beijing: China Union Medical College Press, 2014.
[2] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association. Chinese guideline for diagnosis and management of drug - induced liver injury (2023 version)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2023, 31(4): 355-384.
[3] LI XY, TANG JT, MAO YM.Incidence and risk factors of drug-induced liver injury[J]. Liver international, 2022, 42(9): 1999-2014.
[4] Chinese College of Surgeons. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2023)[J]. Chinese Journal of Digestive Surgery(中华消化外科杂志), 2023, 22(1): 1-28.
[5] TURAL D, AKAR E, MEHMET AO, et al.Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma[J]. Journal of Cancer Research & Therapeutics, 2014, 10(3): 745-748.
[6] Chinese Medical Association.Guideline for primary care of drug-induced liver injury(2019)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(10): 868-875.
[7] DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al.Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines[J]. Hepatology international, 2021, 15(2): 258-282.
[8] ZENG D.Angelica Polysaccharide Alleviated Liver Injury Induced by 5-Fluorouracil by Regulating NRF2/HO-1 Signaling Pathway[D]. Chongqing Medical University, 2022.
[9] ZORZI D, LAURENT A, PAWLIK TM, et al.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases[J]. The British journal of surgery, 2007, 94(3): 274-286.
[10] WANG F, CHEN SC, CAO NY, et al.Effect of irinotecan combined with cetuximab on liver function and histology in patients with advanced colorectal cancer and liver metastasis[J]. Chinese Journal of Clinical Oncology and Rehabilitation(中国肿瘤临床与康复), 2016, 23(9): 1047-1050.
[11] HAN J, LIU J, YU Z, et al.Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China[J]. British Medical Journal Open, 2023, 13(6):e069794.
[12] LI J, CHEN B, XI WQ, et al.Drug-drug interactions and disease status are associated with irinotecan-induced hepatotoxicity: a cross-sectional study in Shanghai[J]. Journal of Clinical Pharmacology, 2022, 62(9): 1160-1169.
[13] National Center for Clinical Research of Infectious Disease. Expect consensus on the diagnosis and treatment of intrahepatic cholestasis (2021 edition)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2022, 30(2): 137-146.
[14] TIAN YJ, WANG JP, LEI XP, et al.Effect of ursodeoxycholic acid on acute liver injury induced by antitumor drugs and its effect on T lymphocyte subsets[J]. Chinese Hepatology(肝脏), 2020, 25(1): 73-75.
[15] CHEN J.Observation on the effect of adenosylmethionine combined with ursodeoxycholic acid in the treatment of cholestatic drug-induced liver injury[J]. Zhejiang Practical Medicine(浙江实用医学), 2015, 20(4): 239-240.
[16] LI RR, LI M, GOU Y, et al.Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(5): 505-510.
[17] Medical Affairs Department of the National Health Commission. Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2023, 14(4): 706-733.
[18] FOLPRECHT G, GRUENBERGER T, BECHSTEIN W, et al.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)[J]. Annals of oncology, 2014, 25(5): 1018-1025.
[19] FANG WT, GU YH.Medication options for colorectal cancer with complications[J]. Chinese Journal of Colorectal Diseases(Electronic Edition)(中华结直肠疾病电子杂志), 2018, 7(5): 420-430.
[20] RAYMOND E, BOIGE V, FAIVRE S, et al.Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction[J]. Journal of Clinical Oncology, 2002, 20(21): 4303-4312.
[21] Guangdong Pharmaceutical Association.Expert consensus on the clinical application and adverse reaction management of platinum drugs[J]. Pharmacy Today(今日药学), 2019, 29(9): 577-585.
[22] DOROSHOW JH, SYNOLD TW, GANDARA D, et al.Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group[J]. Seminars in Oncology, 2003, 30(4 Suppl 15): 14-19.

1例伊立替康致结肠癌患者急性肝损伤的药学监护

Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[2]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[3]	张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.
[4]	严妍, 刘乃一, 乔玲, 张毅, 杨晨. 别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析[J]. 中国药物警戒, 2024, 21(9): 1068-1070.
[5]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[6]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[7]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[8]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[9]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[10]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[11]	晁滢, 张学梅, 张成健, 王贝. 注射用头孢曲松钠致儿童输尿管结石及胆囊结石1例分析[J]. 中国药物警戒, 2024, 21(8): 943-945.
[12]	郭海嬿, 何波, 闫鸿丽, 杨雪婷. 稳心颗粒致持续性呃逆1例分析[J]. 中国药物警戒, 2024, 21(8): 946-948.
[13]	王丹, 董铎, 田春华. 我国药物警戒制度发展历程和思考[J]. 中国药物警戒, 2024, 21(7): 735-740.
[14]	邵波, 郭晓昕. 中药药物警戒回顾与思考[J]. 中国药物警戒, 2024, 21(7): 741-745.
[15]	阿拉腾花, 王振兴, 张晓朦, 世伟, 席成伟, 王聪慧, 王立群, 张冰. 基于药品不良反应监测数据的心脏器官伤害风险信号挖掘分析[J]. 中国药物警戒, 2024, 21(7): 752-758.